Passage Bio, Inc.
PASG
$7.48
-$0.065-0.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.57% | -6.60% | -25.03% | -11.40% | -19.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.00% | -23.42% | -22.64% | -31.68% | -33.28% |
| Operating Income | 39.00% | 23.42% | 22.64% | 31.68% | 33.28% |
| Income Before Tax | 41.31% | 7.82% | 24.07% | 28.66% | 32.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.31% | 7.82% | 24.07% | 28.66% | 32.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.31% | 7.82% | 24.07% | 28.66% | 32.97% |
| EBIT | 39.00% | 23.42% | 22.64% | 31.68% | 33.28% |
| EBITDA | 37.03% | 21.01% | 23.18% | 32.14% | 33.87% |
| EPS Basic | 41.80% | 16.44% | 32.63% | 36.72% | 41.68% |
| Normalized Basic EPS | 40.16% | 30.75% | 32.63% | 40.59% | 43.28% |
| EPS Diluted | 41.80% | 16.44% | 32.63% | 36.72% | 41.68% |
| Normalized Diluted EPS | 40.16% | 30.75% | 32.63% | 40.59% | 43.28% |
| Average Basic Shares Outstanding | 0.84% | 10.33% | 12.72% | 12.73% | 14.93% |
| Average Diluted Shares Outstanding | 0.84% | 10.33% | 12.72% | 12.73% | 14.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |